Integrins as attractive targets for cancer therapeutics

Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development.

Abstract licence: CC BY-NC-ND

• CRISPR/Cas9 therapeutics: progress and prospects · 2023

• Angiogenic signaling pathways and anti-angiogenic therapy for cancer · 2023

• Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets · 2023

• The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis · 2022

• Targeting Integrins for Cancer Therapy - Disappointments and Opportunities · 2022

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.